TMCnet News

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Celladon Corporation and Advises Shareholders to Contact the Firm Prior to the Lead Plaintiff Deadline
[July 06, 2015]

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Celladon Corporation and Advises Shareholders to Contact the Firm Prior to the Lead Plaintiff Deadline


Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California against Celladon Corporation ("Celladon" or the "Company") (NASDAQ: CLDN), for alleged violations of the federal securities laws. Investors who purchased or otherwise acquired shares between July 7, 2014 and June 25, 2015, inclusive (the "Class Period"), have until August 31, 2015 to serve as lead plaintiff in the class action. In addition, investors who purchased shares traceable to the Company's Initial Public Offering ("IPO") on January 30, 2014, should contact the firm to discuss this action.

If you are a shareholder who suffered a loss during th Class Period, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA (News - Alert) 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm's website at http://www.Goldberglawpc.com, or by email at [email protected].



The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Celladon is a biotechnology company focused on developing gene therapies for cardiovascular diseases. The complaint alleges that the Company made false and/or misleading statements and failed to disclose adverse information regarding MYDICAR, its lead drug candidate for the treatment of enzyme deficiency in patients experiencing heart failure. On April 26, 2015, the Company reported that its Phase 2b CUPID2 trial of MYDICAR did not meet its primary and secondary goals. The Company had omitted to mention that the CUPID1 trial was significantly smaller, and that success from the first trial was not indicative of any success in the CUPID2 trial. When the truth was revealed, the stock dropped causing damage to investors.


If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at [email protected].

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


[ Back To TMCnet.com's Homepage ]